Artículos por temáticas

Recent Insights on the Role of Nuclear Receptors in Alzheimer's Disease: Mechanisms and Therapeutic Application

Shan X, Li D, Yin H, Tao W, Zhou L, Gao Y, Xing C, Zhang C.

Int J Mol Sci. 2025 Jan 30;26(3):1207. doi: 10.3390/ijms26031207.

Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment

Jang YJ, Kang SJ, Park HS, Lee DH, Kim JH, Kim JE, Kim DI, Chung CH, Yoon JK, Bhang SH.

J Nanobiotechnology. 2025 Feb 10;23(1):99. doi: 10.1186/s12951-025-03109-3.

Quercetin-functionalized nanomaterials: Innovative therapeutic avenues for Alzheimer's disease management

Pei J, Kumarasamy RV, Jayaraman S, Kanniappan GV, Long Q, Palanisamy CP.

Ageing Res Rev. 2025 Feb;104:102665. doi: 10.1016/j.arr.2025.102665. Epub 2025 Jan 15.

The effects of transcranial direct current stimulation on global cognition in patients with Alzheimer's disease: An update meta-analysis

Su S, Huang R, Liu Y.

J Alzheimers Dis. 2025 Jan;103(1):19-37. doi: 10.1177/13872877241298303. Epub 2025 Jan 9.

Effects of aerobic exercise on cognitive function and quality of life in patients with Alzheimer's disease: a systematic review and meta-analysis

Yang L, Yuan Z, Peng C.

BMJ Open. 2025 Jan 11;15(1):e090623. doi: 10.1136/bmjopen-2024-090623.

Neural mechanisms of non-pharmacological interventions in patients with mild cognitive impairment and Alzheimer's disease: An ALE meta-analysis

Wang N, Li J, Guo Y, Zhang P, You F, Wang Z, Wang Z, Hong X.

Exp Gerontol. 2025 Feb;200:112678. doi: 10.1016/j.exger.2025.112678. Epub 2025 Jan 9.

Modulating Neuroinflammation as a Prospective Therapeutic Target in Alzheimer's Disease

Lee E, Chang Y.

Cells. 2025 Jan 22;14(3):168. doi: 10.3390/cells14030168.

Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial

Macfarlane S, Grimmer T, Teo K, O'Brien TJ, Woodward M, Grunfeld J, Mander A, Brodtmann A, Brew BJ, Morris P, Short C, Kurrle S, Lai R, Bharadwaj S, Drysdale P, Sturm J, Lewis SJG, Barton D, Kalafatis

J Prev Alzheimers Dis. 2025 Jan;12(1):100016. doi: 10.1016/j.tjpad.2024.100016. Epub 2025 Jan 1.

Phosphodiesterase 4 Inhibition in Neuropsychiatric Disorders Associated with Alzheimer's Disease

Chen J, Zhu Z, Xu F, Dou B, Sheng Z, Xu Y.

Cells. 2025 Jan 22;14(3):164. doi: 10.3390/cells14030164.

Examining the role of antioxidant supplementation in mitigating oxidative stress markers in Alzheimer's disease: a comprehensive review

Jawad M, Uthirapathy S, Altalbawy FMA, Oghenemaro EF, Rizaev J, Lal M, Eldesoqui M, Sharma N, Pramanik A, Al-Hamairy AK.

Inflammopharmacology. 2025 Feb;33(2):573-592. doi: 10.1007/s10787-024-01622-9. Epub 2024 Dec 19.

Role of OX/OXR cascade in insomnia and sleep deprivation link Alzheimer's disease and Parkinson's disease: Therapeutic avenue of Dual OXR Antagonist (DORA)

Panda SP, Sinha S, Kesharwani A, Kumar S, Singh M, Kondepudi GM, Samuel A, Sanghi AK, Thapliyal S, Chaubey KK, Guru A.

Biochem Pharmacol. 2025 Mar;233:116794. doi: 10.1016/j.bcp.2025.116794. Epub 2025 Feb 5.

Myeloperoxidase as a therapeutic target for oxidative damage in Alzheimer's disease

Rivera Antonio AM, Padilla Martínez II, Torres-Ramos MA, Rosales-Hernández MC.

J Enzyme Inhib Med Chem. 2025 Dec;40(1):2456282. doi: 10.1080/14756366.2025.2456282. Epub 2025 Feb 14.

Reinforcing Nrf2 Signaling: Help in the Alzheimer's Disease Context

la Torre A, Lo Vecchio F, Angelillis VS, Gravina C, D'Onofrio G, Greco A.

Int J Mol Sci. 2025 Jan 28;26(3):1130. doi: 10.3390/ijms26031130.

Current Status of Plant-Based Bioactive Compounds as Therapeutics in Alzheimer's Diseases

Chen D, Sun Y.

J Integr Neurosci. 2025 Jan 20;24(1):23090. doi: 10.31083/JIN23090.

Ellagic Acid: A Green Multi-Target Weapon That Reduces Oxidative Stress and Inflammation to Prevent and Improve the Condition of Alzheimer's Disease

Alfei S, Zuccari G.

Int J Mol Sci. 2025 Jan 20;26(2):844. doi: 10.3390/ijms26020844.